Targets › HADH
1 program from 1 company in 1 trial: 1 Phase 3; Other; next expected readout Dec 2026.
Mitochondrial fatty acid beta-oxidation enzyme that catalyzes the third step of the beta-oxidation cycle for medium and short-chain 3-hydroxy fatty acyl-CoAs (C4 to C10). Plays a role in the control of insulin secretion by inhibiting the activation of glutamate dehydrogenase 1 (GLUD1), an enzyme that has an important role in regulating amino acid-induced insulin secretion (By similarity). (UniProt, Q16836)
Open in Phaseline: the race on HADH, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ain Shams University | Trimetazidine 3-ketoacyl-CoA thiolase inhibitor; shifts cardiac energy metabolism from fatty acid oxidat | HADH | Phase 3 | Aluminum Phosphide Poisoning | Dec 2026 |
Aluminum Phosphide Poisoning (1)
small molecule (1)
Ain Shams University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.